charlie campion technology development manager, biosurgery r&d, baxter healthcare corp
DESCRIPTION
ApaTech as an example of how “academia / industry partnerships” can overcome barriers to commercialization of regenerative medicine products. TERMIS 2012 Vienna, 7 th September 2012. Charlie Campion Technology Development Manager, Biosurgery R&D, Baxter Healthcare Corp. . - PowerPoint PPT PresentationTRANSCRIPT
1
Charlie Campion Technology Development Manager, Biosurgery R&D, Baxter
Healthcare Corp.
ApaTech as an example of how “academia / industry partnerships” can
overcome barriers to commercialization of regenerative medicine products
TERMIS 2012 Vienna, 7th September 2012
2
Since the acquisition in 2010, ApaTech products have formed part of the Biosurgery portfolio at Baxter
ACTIFUSE ABX ACTIFUSE MISACTIFUSE SHAPE
ApaTech specializes in developing and manufacturing synthetic bone repair products for the global orthobiologics market
ACTIFUSE GRANULES/ MICROGRANULES
ACTIFUSE EZ-PREP
3
Barriers to Market Entry
There are many challenges which new companies face when entering the healthcare market
Development Funding
Sales & Distribution
Regulatory Complexity
Surgeon Advocacy
Time to Product Launch
Manufacturing Capacity
4
Rapid growth
Although not the only success factor, academic partnerships have been fundamental to growth at ApaTech
Award-winning sales growth180% yr/yr 2006-2009
Publications
Capacity expansion1L : 1600L
upscaling factor in 7 yrs
Process experts
Portfolio development
5 new products in 5 years
Research data
Investor confidence£32.5M of
funding in 7yrs (3 rounds)
Prestige
5
Materials Processing
Ageing
Surface Science
Humanities Biomedical Materials
Earth, Planetary, Space and Astronomy
Nanotechnology
ApaTech has academic roots: ApaTech was founded in 2001 as a spin-out from the IRC, Queen Mary, UoL
In the 1990’s the UK government funded specialised centres of research to promote the growth of UK research and manufacturing
6
Formed in 1991
Professor Bill Bonfield
£10 million funding
Multi-centre approach:
Institute of Orthopaedics at UCL
IRC Biomedical Materials
There was an established pedigree for bone research within the centre which ApaTech were able to leverage in the early days of commercialisation
77
University of London – IRC in Biomedical Materials Bone functions as a mineral reservoir for the body Porous bone graft substitutes comprised of thermally
transformed Bovine and Coralline Hydroxyapatite were already in clinical use for bone grafting
Research Questions: Do low-level ionic substitutions play a role in the biology of
bone repair? What is the role of a bone graft substitute’s structure in the
biology of bone repair?
A multi-disciplinary approach was applied to the common research goal of the IRC : how can we develop superior synthetic bone grafts?
8
Professor Iain Gibson BSc (Hons), PhD
− Ionic substitutions− Metabolic role of
minerals in bone− Further increase
in cellular response
Do low-level ionic substitutions play a role in the biology of bone repair?
Professor Gibson now has a chair at University of Aberdeen where his research is based on guiding cell behaviour during tissue repair and wound healing, using
physico-chemical guidance cues
9
Dr Karin Hing CEng, PhD, BSc, MIMMM, FRMS
− Foaming ceramics− Porous HA− Increased cellular
response
What is the role of a bone graft substitute’s structure in the biology of bone repair?
Dr Hings’s research group at QM is now engaged in physico-chemical and hierarchical 3-D structural characterisation of bone grafts, the study of protein
interactions, cell response and chemotaxis
10
ApaTech continued to expand it’s network of academic partners throughout the UK & across the Globe
11
ApaTech used a variety of mechanisms to partner with academic research centres
Academic Research
Centre
PhD Studentships
Consultancy Contracts
Contract Services
Student Award Sponsorship
MSC student Funding
Undergraduate Project
Mentoring
Symposia Sponsorship
IP Purchase agreements
12
ApaTech continue to leverage subject matter expertise in Academia to get products to market
33%
67%
Proportion of regulatory non-clinical studies *
Contract Research OrganisationAcademic Research Centre
Portfolio development
5 new products in 5 yearsReg. Data
* Data for the period between 1st round funding up to Baxter Healthcare acquisition (2001 – 2010)
13
ApaTech continue to leverage subject matter expertise in Academia to develop product pipeline
67%
33%
Proportion of patents granted or pending by ori-
gin *
ApaTech Academic Research Centre
Portfolio development
5 new products in 5 yearsReg. Data
* Data for the period between 1st round funding up to Baxter Healthcare acquisition (2001 – 2010)
14
ApaTech continue to use their academic pedigree to provide robust mechanistic data to support sales
3%
97%
Proportion of supporting publications (1st author) *
ApaTech EmployeeAcademia Based Researcher
Award-winning sales growth200% yr/yr 2007-2009
Publications
* Data for the period between 1st round funding up to Baxter Healthcare acquisition (2001 – 2010)
15
Summary
ApaTech was founded in Academia and was able to leverage its pedigree to keep investors on-board. ApaTech
continued to partner with Global academic centres to reduce time-to-market whilst building a robust scientific
story around the commercialised technology.
The way forward:
ApaTech have demonstrated there are a number of mechanisms by which Industry can interact with Academia
in order to minimise the impact of barriers to market, whilst developing the next generation of scientific
advocates for the commercialised technology.
16
Acknowledgements
− Professor Heinz Redl for my invitation
− The co-founders of ApaTech and the investors who believed in them
− All Academic research centres ApaTech have collaborated with since commercialisation began in 1999